Double maintains 1 strategies that include FATE - Fate Therapeutics, Inc.
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| UTZ | <0.01% | $1.13B | -19.50% | 1.85% |
| THC | -0.01% | $16.48B | +32.17% | 0.00% |
| TXO | 0.04% | $826.70M | -27.45% | 15.71% |
| WELL | -0.05% | $99.14B | +43.06% | 1.77% |
| FRO | 0.06% | $3.67B | -34.81% | 8.08% |
| RRC | 0.08% | $9.31B | +14.08% | 0.87% |
| ARMK | 0.10% | $11.11B | +27.63% | 0.97% |
| MKC | -0.11% | $20.70B | +9.87% | 2.25% |
| MOMO | -0.12% | $1.01B | +46.56% | 0.00% |
| IMNN | 0.14% | $15.87M | -37.00% | 0.00% |
| MDLZ | -0.15% | $89.29B | +4.44% | 2.72% |
| XEL | 0.17% | $39.63B | +29.15% | 3.31% |
| AMPY | -0.17% | $132.30M | -51.84% | 0.00% |
| HSY | -0.19% | $35.62B | -4.79% | 3.11% |
| ACGL | 0.19% | $34.29B | -3.78% | 0.00% |
| TEN | -0.20% | $587.79M | -34.02% | 7.64% |
| SRRK | 0.20% | $3.21B | +342.46% | 0.00% |
| AMSF | -0.22% | $832.88M | +5.01% | 3.52% |
| TIMB | -0.24% | $9.79B | +45.56% | 2.02% |
| EXE | 0.25% | $26.46B | +33.93% | 2.07% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| BTAL | -33.39% | $295.67M | 1.43% |
| VIXY | -23.22% | $165.58M | 0.85% |
| SHYD | -16.03% | $332.28M | 0.35% |
| DFNM | -15.99% | $1.57B | 0.17% |
| BSMR | -14.67% | $255.65M | 0.18% |
| VRIG | -14.59% | $1.20B | 0.3% |
| TAIL | -13.94% | $99.49M | 0.59% |
| MLN | -13.55% | $540.39M | 0.24% |
| CTA | -13.44% | $1.06B | 0.76% |
| FMHI | -13.22% | $753.22M | 0.7% |
| BSMW | -12.93% | $107.29M | 0.18% |
| PZA | -12.64% | $2.84B | 0.28% |
| PWZ | -12.47% | $748.91M | 0.28% |
| SMB | -12.43% | $274.79M | 0.07% |
| TAXF | -12.02% | $488.67M | 0.29% |
| AGZD | -11.95% | $102.60M | 0.23% |
| ITM | -11.69% | $1.87B | 0.18% |
| STPZ | -11.58% | $450.05M | 0.2% |
| VTIP | -11.02% | $15.34B | 0.03% |
| CMF | -10.77% | $3.58B | 0.08% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CRBU | 56.25% | $116.26M | -21.88% | 0.00% |
| CRSP | 55.80% | $4.19B | -8.67% | 0.00% |
| ALLO | 54.76% | $258.10M | -45.37% | 0.00% |
| RXRX | 54.74% | $2.09B | -28.35% | 0.00% |
| NTLA | 53.62% | $1.02B | -55.40% | 0.00% |
| BEAM | 51.28% | $1.76B | -22.33% | 0.00% |
| IMNM | 47.77% | $736.56M | -27.65% | 0.00% |
| YMAB | 47.27% | $199.75M | -61.21% | 0.00% |
| RGNX | 46.92% | $414.70M | -23.44% | 0.00% |
| MGNX | 46.43% | $79.49M | -69.27% | 0.00% |
| ABCL | 46.39% | $1.04B | +25.99% | 0.00% |
| IGMS | 46.25% | $77.55M | -79.84% | 0.00% |
| CGEM | 45.86% | $450.87M | -53.16% | 0.00% |
| ARWR | 44.46% | $2.22B | -36.20% | 0.00% |
| ZNTL | 44.26% | $85.62M | -66.67% | 0.00% |
| GBIO | 43.52% | $21.45M | -86.32% | 0.00% |
| KURA | 43.18% | $484.82M | -72.79% | 0.00% |
| EDIT | 42.73% | $188.35M | -50.44% | 0.00% |
| DNLI | 42.16% | $2.03B | -35.83% | 0.00% |
| IDYA | 42.10% | $1.85B | -37.37% | 0.00% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| ARKG | 53.25% | $1.02B | 0.75% |
| GNOM | 51.90% | $44.38M | 0.5% |
| XBI | 46.30% | $4.84B | 0.35% |
| IWC | 43.56% | $817.74M | 0.6% |
| PTH | 39.11% | $100.70M | 0.6% |
| IBB | 38.28% | $5.28B | 0.45% |
| IWM | 37.13% | $63.18B | 0.19% |
| VTWO | 36.94% | $12.58B | 0.07% |
| PINK | 36.81% | $129.96M | 0.5% |
| IWN | 36.65% | $10.93B | 0.24% |
| IWO | 36.32% | $11.53B | 0.24% |
| ARKK | 36.24% | $6.78B | 0.75% |
| GSSC | 35.76% | $560.96M | 0.2% |
| CPRJ | 35.58% | $48.21M | 0.69% |
| PBE | 35.00% | $223.86M | 0.58% |
| KJUL | 34.72% | $119.28M | 0.79% |
| RDTE | 34.16% | $137.58M | 0.97% |
| SCHA | 33.94% | $17.26B | 0.04% |
| IWMY | 33.91% | $118.77M | 1.02% |
| PRFZ | 33.91% | $2.36B | 0.34% |
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| MINT | -<0.01% | $13.33B | 0.35% |
| SPSB | -0.03% | $8.35B | 0.04% |
| MINO | -0.04% | $319.43M | 0.39% |
| DBA | 0.05% | $792.17M | 0.93% |
| FXE | 0.05% | $578.76M | 0.4% |
| SPAB | 0.07% | $8.79B | 0.03% |
| IYK | -0.09% | $1.45B | 0.4% |
| TLT | -0.09% | $48.46B | 0.15% |
| EDV | 0.10% | $3.45B | 0.05% |
| FLRT | 0.11% | $508.97M | 0.6% |
| SPTL | -0.11% | $11.23B | 0.03% |
| BKAG | -0.14% | $1.90B | 0% |
| FXC | 0.15% | $93.05M | 0.4% |
| NUBD | -0.15% | $396.52M | 0.16% |
| FLCB | -0.15% | $2.59B | 0.15% |
| KBA | 0.19% | $174.39M | 0.56% |
| UBND | -0.20% | $1.02B | 0.4% |
| WEAT | 0.21% | $117.67M | 0.28% |
| IBDV | 0.22% | $1.90B | 0.1% |
| STXT | 0.25% | $128.98M | 0.49% |
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| NOC | -14.66% | $72.47B | +15.13% | 1.72% |
| K | -13.00% | $27.71B | +40.85% | 2.85% |
| CBOE | -12.65% | $24.29B | +35.36% | 1.09% |
| KMB | -12.32% | $43.67B | -4.62% | 3.76% |
| BULL | -12.26% | $5.80B | +12.65% | 0.00% |
| CME | -12.10% | $99.25B | +39.75% | 3.87% |
| HUSA | -10.44% | $21.26M | -8.69% | 0.00% |
| EQNR | -10.20% | $69.02B | -7.55% | 5.56% |
| CTRE | -9.38% | $5.84B | +20.16% | 4.10% |
| ACI | -9.00% | $12.20B | +8.96% | 2.48% |
| KR | -8.89% | $47.17B | +41.48% | 1.81% |
| TEF | -8.89% | $30.02B | +27.27% | 6.13% |
| INGR | -8.74% | $8.80B | +21.33% | 2.92% |
| ENIC | -8.44% | $5.04B | +38.26% | 0.21% |
| CQP | -7.43% | $26.78B | +12.30% | 5.93% |
| ED | -7.12% | $36.31B | +13.27% | 3.35% |
| LITB | -6.99% | $22.07M | -77.41% | 0.00% |
| PGR | -6.96% | $154.94B | +25.19% | 1.87% |
| CHD | -6.92% | $24.05B | -7.40% | 1.18% |
| TTE | -6.67% | $138.17B | -9.82% | 5.58% |
Current Value
$1.141 Year Return
Current Value
$1.141 Year Return
Finnhub
Fate Therapeutics, Inc. added to Russell 3000E Index...
Finnhub
Fate Therapeutics, Inc. added to Russell Microcap Index...
Finnhub
Fate Therapeutics, Inc. added to Russell Microcap Value Index...
Finnhub
Fate Therapeutics, Inc. added to Russell 3000E Value Index...
Yahoo
Fate Therapeutics (FATE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up continues in drug-free Definition of Remission in SLE (DORIS) First extrarenal SLE patient on maintenance therapy treated with FT819 in the absence of conditioning achieves Low Lupus Disease Activity State (LLDAS) at 3-month follow-up and maintained at 6 months Cumulative clinical experience in nea
